文献速递免疫规划传染病防控与疫情报告

厄瓜多尔肺炎球菌结合疫苗对儿童和老年人肺炎住院及死亡的影响:时间序列分析

Impact of pneumococcal conjugate vaccine on pneumonia hospitalization and mortality in children and elderly in Ecuador: Time series analyses.
PubMed 文献 · Vaccine · 2020-09-25

该研究利用厄瓜多尔2005至2015年全国二级数据,采用时间序列回归模型评估2010年引入PCV后对5岁以下儿童和50岁及以上成人全因肺炎住院与死亡的影响。结果显示PCV对1岁以下和5岁以下儿童肺炎住院有显著下降,对部分年龄组肺炎死亡也有下降,但65岁及以上老年人变化证据有限。

要点

  • PCV使1岁以下儿童肺炎住院减少27%(95%CI 12-42%)。
  • PCV使5岁以下儿童肺炎住院减少33%(95%CI 11-43%)。
  • PCV使50-64岁成人肺炎死亡减少22%(95%CI 7-34%)。

核心结论

  • PCV对厄瓜多尔1岁以下和5岁以下儿童肺炎住院有显著影响,对50-64岁成人肺炎死亡也有下降,但65岁及以上老年人变化证据有限。

研究设计与样本

  • 利用厄瓜多尔2005至2015年全国二级数据,采用时间序列回归模型分析PCV引入后肺炎住院和死亡的变化,目标人群为5岁以下儿童和50岁及以上成人。

主要发现

  • PCV使1岁以下儿童肺炎住院减少27%(95%CI 12-42%),5岁以下儿童减少33%(95%CI 11-43%)。
  • PCV使1岁以下儿童肺炎死亡减少14%(95%CI 0-33%),5岁以下减少10%(95%CI 0-25%),50-64岁成人减少22%(95%CI 7-34%)。
  • 65岁及以上老年人肺炎死亡变化证据有限。

临床怎么用

  • 研究结果可为政策制定者和全球资助者评估PCV在儿童和老年人中的公共卫生影响提供依据。

局限性

  • 需要进一步研究PCV对老年人的间接效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pneumococcal conjugate vaccines (PCV) reduce the burden of invasive pneumococcal disease and pneumonia hospitalizations. However, there is limited evidence of the effect of PCVs on pneumonia mortality in children. It is anticipated that indirect effects resulting from PCV use among children might further reduce the remaining burden of adult pneumococcal disease caused by pneumococcal serotypes contained in PCV. Whether this will result in reduced pneumonia mortality in children and adults is still not known. METHODS: We investigated the impact of PCV on pneumonia hospitalization and mortality in in Ecuador, where PCV was introduced in 2010, considering national data from secondary data sources from 2005 to 2015. Time series analysis using regression models were used to evaluate the decline in the number of all-cause pneumonia hospitalizations and deaths in the period post-PCV introduction. The target populations were children under 5 years and adults aged 50 years and over. Outcomes of interest were hospitalizations and mortality in which the main cause of hospital admission and death, respectively, were coded as ICD10 codes J12-18 (pneumonia). Three different models were fitted. RESULTS: We demonstrate a sizeable impact of PCV in pneumonia hospitalization in children < 1 year (27% reduction, 95%CI 12-42%), and < 5 years of age (33% reduction, 95%CI 11-43%). The estimated impact of PCV in pneumonia mortality was a reduction of 14% in < 1 year (95%CI 0-33%), 10% in < 5 years (95%CI 0-25%), and 22% (95%CI 7-34%) in adults aged 50-64 years. Little evidence of a change was detected in elderly ≥ 65 years. CONCLUSION: This study is the first to report on the impact of PCV in pneumonia morbidity and mortality in children and older adults, being relevant to policy makers and global donors. Findings were consistent when using different models. Additional studies on the indirect effect of PCV in older adults are needed.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Jimbo Sotomayor R, Toscano CM, Sánchez Choez X, et al. Impact of pneumococcal conjugate vaccine on pneumonia hospitalization and mortality in children and elderly in Ecuador: Time series analyses. Vaccine. 2020. PMID: 32981782. doi:10.1016/j.vaccine.2020.09.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。